ZYUS Life Sciences Corporation (TSXV:ZYUS)

Market Cap	52.27M
Revenue (ttm)	481.00K
Net Income (ttm)	-34.43M
Shares Out	78.01M
EPS (ttm)	-0.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	850
Average Volume	11,560
Open	0.7200
Previous Close	0.6700
Day's Range	0.7100 - 0.7200
52-Week Range	0.5500 - 1.0400
Beta	0.95
RSI	45.17
Earnings Date	Aug 28, 2025

About ZYUS Life Sciences

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: ZYUS

Financial Performance

In 2024, ZYUS Life Sciences's revenue was 481,000, an increase of 37.04% compared to the previous year's 351,000. Losses were -33.81 million, -20.63% less than in 2023.